Foghorn Therapeutics Inc. (FHTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Foghorn Therapeutics Inc. (FHTX) closed at USD 1.85 on 2026-10-14, a change of -58.4 % over the past year, with a market capitalization of USD 112.24M.

Foghorn Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Foghorn Therapeutics Inc. key figures

Previous close

USD 1.85 (2026-10-14)

1-year change

-58.4 %

Market cap

USD 112.24M

Enterprise value

USD -12.24M

P/E ratio (trailing)

-1.89

P/E ratio (forward)

-1.84

EPS (trailing)

-1.00

EPS (forward)

-1.03

PEG ratio

n/a

Price to book

-1.37

Revenue growth

112.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.85

Employees

106

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Foghorn Therapeutics Inc. and compare it with other stocks.